Payment overview · 2025
General Payments
$210.61
8 reported records · 6 companies
Healthcare provider profile · identity verified
Latrice Janiva Shell
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · AIKEN, SC · NPI 1528783065
Verified facts
What the public records show
CMS Open Payments records show Latrice Janiva Shell received $210.61 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.82 | 44.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.85 | 17.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.23 | 11.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.32 | 11.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.89 | 8.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.50 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $210.61 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 162 |
| Lisinopril | Lisinopril | 265 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 86 |
| Tramadol Hcl | Tramadol Hcl | 209 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 81 |
| Omeprazole | Omeprazole | 201 | 84 |
| Gabapentin | Gabapentin | 195 | 73 |
| Metformin Hcl | Metformin Hcl | 191 | 69 |
| Meloxicam | Meloxicam | 170 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 70 |
| Alprazolam | Alprazolam | 144 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 128 | 44 |
| Losartan Potassium | Losartan Potassium | 120 | 52 |
| Sertraline Hcl | Sertraline Hcl | 120 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 52 |
| Glipizide | Glipizide | 108 | 37 |
| Potassium Chloride | Potassium Chloride | 108 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 25 |
| Famotidine | Famotidine | 105 | 38 |
| Simvastatin | Simvastatin | 101 | 38 |
| Januvia | Sitagliptin Phosphate | 98 | 24 |
| Furosemide | Furosemide | 95 | 44 |
| Fenofibrate | Fenofibrate | 90 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 38 |
| Alendronate Sodium | Alendronate Sodium | 85 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 40 |
| Ezetimibe | Ezetimibe | 80 | 25 |
| Pregabalin | Pregabalin | 79 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 29 |
| Azithromycin | Azithromycin | 75 | 72 |
| Clonazepam | Clonazepam | 75 | 22 |
| Montelukast Sodium | Montelukast Sodium | 75 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 26 |
| Ozempic | Semaglutide | 73 | 17 |
| Allopurinol | Allopurinol | 69 | 29 |
| Buspirone Hcl | Buspirone Hcl | 65 | 25 |
| Carvedilol | Carvedilol | 65 | 25 |
| Celecoxib | Celecoxib | 65 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 26 |
| Farxiga | Dapagliflozin Propanediol | 62 | 26 |
| Aripiprazole | Aripiprazole | 55 | 19 |
| Eliquis | Apixaban | 55 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 25 |
| Jardiance | Empagliflozin | 53 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | 25 |
| Meclizine Hcl | Meclizine Hcl | 45 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Lorazepam | Lorazepam | 43 | 11 |
| Kerendia | Finerenone | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 35 |
| Ibuprofen | Ibuprofen | 36 | 28 |
| Promethazine Hcl | Promethazine Hcl | 36 | 12 |
| Amoxicillin | Amoxicillin | 35 | 33 |
| Atenolol | Atenolol | 33 | 11 |
| Telmisartan | Telmisartan | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 11 |
| Myrbetriq | Mirabegron | 32 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 11 |
| Chlorthalidone | Chlorthalidone | 31 | 13 |
| Spironolactone | Spironolactone | 31 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 15 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ibu | Ibuprofen | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Prednisone | Prednisone | 20 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $210.61 · 8 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, FARXIGA, JARDIANCE, Korlym, LEQVIO, MOUNJARO, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error